Trizivir

Philip Keiser, Naiel Nassar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment of HIV infection has typically been carried out using two nucleoside analogues and a protease inhibitor (PI). Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside based regimens, can improve adherence and decrease toxicities associated with PI therapy. Trizivir™ is a combination tablet of zidovudine, lamivudine and abacavir. This formulation allows a dosing schedule of one pill twice-daily. The components of have performed favourably compared to PI-based regimens, such as indinavir. However, in one study the individual components of Trizivir did not suppress HIV-1 viral replication as well as the PI-based regimen in a subset of patients with very high HIV-1 plasma RNA. Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. Trizivir is an important part of the HIV armamentarium. The potency and ease of administration of Trizivir make it worth consideration in HIV therapy, either by itself or in combination with other agents.

Original languageEnglish (US)
Pages (from-to)619-624
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Protease Inhibitors
Nucleosides
HIV-1
HIV
Indinavir
Zidovudine
Therapeutics
Hyperlipidemias
Tablets
HIV Infections
Appointments and Schedules
Hypersensitivity
Trizivir
RNA

Keywords

  • Abacavir
  • HIV
  • Lamivudine
  • Trizivir
  • Zidovudine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Trizivir. / Keiser, Philip; Nassar, Naiel.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 5, 2002, p. 619-624.

Research output: Contribution to journalArticle

Keiser, Philip ; Nassar, Naiel. / Trizivir. In: Expert Opinion on Pharmacotherapy. 2002 ; Vol. 3, No. 5. pp. 619-624.
@article{486f734392b64389bd00a43d66f092bf,
title = "Trizivir",
abstract = "Treatment of HIV infection has typically been carried out using two nucleoside analogues and a protease inhibitor (PI). Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside based regimens, can improve adherence and decrease toxicities associated with PI therapy. Trizivir™ is a combination tablet of zidovudine, lamivudine and abacavir. This formulation allows a dosing schedule of one pill twice-daily. The components of have performed favourably compared to PI-based regimens, such as indinavir. However, in one study the individual components of Trizivir did not suppress HIV-1 viral replication as well as the PI-based regimen in a subset of patients with very high HIV-1 plasma RNA. Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. Trizivir is an important part of the HIV armamentarium. The potency and ease of administration of Trizivir make it worth consideration in HIV therapy, either by itself or in combination with other agents.",
keywords = "Abacavir, HIV, Lamivudine, Trizivir, Zidovudine",
author = "Philip Keiser and Naiel Nassar",
year = "2002",
doi = "10.1517/14656566.3.5.619",
language = "English (US)",
volume = "3",
pages = "619--624",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Trizivir

AU - Keiser, Philip

AU - Nassar, Naiel

PY - 2002

Y1 - 2002

N2 - Treatment of HIV infection has typically been carried out using two nucleoside analogues and a protease inhibitor (PI). Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside based regimens, can improve adherence and decrease toxicities associated with PI therapy. Trizivir™ is a combination tablet of zidovudine, lamivudine and abacavir. This formulation allows a dosing schedule of one pill twice-daily. The components of have performed favourably compared to PI-based regimens, such as indinavir. However, in one study the individual components of Trizivir did not suppress HIV-1 viral replication as well as the PI-based regimen in a subset of patients with very high HIV-1 plasma RNA. Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. Trizivir is an important part of the HIV armamentarium. The potency and ease of administration of Trizivir make it worth consideration in HIV therapy, either by itself or in combination with other agents.

AB - Treatment of HIV infection has typically been carried out using two nucleoside analogues and a protease inhibitor (PI). Such regimens can be complex and have high pill burdens. Use of alternative regimens, such as triple nucleoside based regimens, can improve adherence and decrease toxicities associated with PI therapy. Trizivir™ is a combination tablet of zidovudine, lamivudine and abacavir. This formulation allows a dosing schedule of one pill twice-daily. The components of have performed favourably compared to PI-based regimens, such as indinavir. However, in one study the individual components of Trizivir did not suppress HIV-1 viral replication as well as the PI-based regimen in a subset of patients with very high HIV-1 plasma RNA. Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. Trizivir is an important part of the HIV armamentarium. The potency and ease of administration of Trizivir make it worth consideration in HIV therapy, either by itself or in combination with other agents.

KW - Abacavir

KW - HIV

KW - Lamivudine

KW - Trizivir

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0036097243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036097243&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.5.619

DO - 10.1517/14656566.3.5.619

M3 - Article

VL - 3

SP - 619

EP - 624

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -